Eagle Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Eagle Wealth Advisors's VRTX Position: Q3 2026 in Review
Eagle Wealth Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 1.5% in Q3 2026, buying an estimated $6.66K and bringing the position to 858 shares worth $449K. The position accounts for 0.33% of the portfolio, ranked #61.
Eagle Wealth Advisors first reported a position in VRTX in Q4 2025 and has held it in 4 quarters since. 1,798 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- Eagle Wealth Advisors held 858 shares of Vertex Pharmaceuticals worth $449K as of Q3 2026.
- Eagle Wealth Advisors bought 13 Vertex Pharmaceuticals shares in Q3 2026, an estimated $6.66K.
- Vertex Pharmaceuticals made up 0.33% of Eagle Wealth Advisors's portfolio in Q3 2026, its #61 holding.
- Eagle Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
- 1,798 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on Eagle Wealth Advisors's 13F filing for Q3 2026, filed 20 Oct 2026.